Consequently, the investigation ultimately determined that the therapeutic approach involving the combined use of IL-2 and IFN-α exhibited more ineffectiveness in addressing the conditions presented by the NSCLC patients (64). The gene discussed is IL2; the disease is non-small cell lung carcinoma.